Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: Past, present, and future

Takeshi Aihara, Eiji Nakamura, Kikuko Amagase, Kazuyoshi Tomita, Teruaki Fujishita, Kazuharu Furutani, Susumu Okabe

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Pharmacological agents, such as histamine H2 receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of receptors, enzymes, and cytoplasmic signal transduction systems, further possibilities exist for the development of effective antisecretory pharmacotherapy. Gastrin CCK2 receptor antagonists and locally active agents appear to represent promising therapies for the future. Development of gene targeting techniques has allowed production of genetically engineered transgenic and knockout mice. Such genetic technology has increased the investigative power for pharmacotherapy for not only antisecretory agents, but also treatment of mucosal diseases, such as atrophy, hyperplasia, and cancer. Elucidation of the origin of gastric parietal cells also represents an interesting investigative target that should allow a better understanding of not only acid-related diseases, but also the evolution of the stomach as an acid-secreting organ.

Original languageEnglish (US)
Pages (from-to)109-127
Number of pages19
JournalPharmacology and Therapeutics
Volume98
Issue number1
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Gastric Acid
Digestion
Pharmacology
Cholecystokinin B Receptor
Acids
Gastric Parietal Cells
Histamine H2 Antagonists
Drug Therapy
Peptic Esophagitis
Gene Targeting
Therapeutics
Cytoplasmic and Nuclear Receptors
Peptic Ulcer
Knockout Mice
Transgenic Mice
Atrophy
Hyperplasia
Signal Transduction
Stomach
Technology

Keywords

  • Gastric acid secretion
  • Gastrin/CCK receptor
  • H receptor
  • Histidine decarboxylase
  • M receptor
  • Ulcer disease

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease : Past, present, and future. / Aihara, Takeshi; Nakamura, Eiji; Amagase, Kikuko; Tomita, Kazuyoshi; Fujishita, Teruaki; Furutani, Kazuharu; Okabe, Susumu.

In: Pharmacology and Therapeutics, Vol. 98, No. 1, 01.04.2003, p. 109-127.

Research output: Contribution to journalReview article

Aihara, Takeshi ; Nakamura, Eiji ; Amagase, Kikuko ; Tomita, Kazuyoshi ; Fujishita, Teruaki ; Furutani, Kazuharu ; Okabe, Susumu. / Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease : Past, present, and future. In: Pharmacology and Therapeutics. 2003 ; Vol. 98, No. 1. pp. 109-127.
@article{c2aa7dc4f52a4b1b87412019d8b45f55,
title = "Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: Past, present, and future",
abstract = "Pharmacological agents, such as histamine H2 receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of receptors, enzymes, and cytoplasmic signal transduction systems, further possibilities exist for the development of effective antisecretory pharmacotherapy. Gastrin CCK2 receptor antagonists and locally active agents appear to represent promising therapies for the future. Development of gene targeting techniques has allowed production of genetically engineered transgenic and knockout mice. Such genetic technology has increased the investigative power for pharmacotherapy for not only antisecretory agents, but also treatment of mucosal diseases, such as atrophy, hyperplasia, and cancer. Elucidation of the origin of gastric parietal cells also represents an interesting investigative target that should allow a better understanding of not only acid-related diseases, but also the evolution of the stomach as an acid-secreting organ.",
keywords = "Gastric acid secretion, Gastrin/CCK receptor, H receptor, Histidine decarboxylase, M receptor, Ulcer disease",
author = "Takeshi Aihara and Eiji Nakamura and Kikuko Amagase and Kazuyoshi Tomita and Teruaki Fujishita and Kazuharu Furutani and Susumu Okabe",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0163-7258(03)00015-9",
language = "English (US)",
volume = "98",
pages = "109--127",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease

T2 - Past, present, and future

AU - Aihara, Takeshi

AU - Nakamura, Eiji

AU - Amagase, Kikuko

AU - Tomita, Kazuyoshi

AU - Fujishita, Teruaki

AU - Furutani, Kazuharu

AU - Okabe, Susumu

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Pharmacological agents, such as histamine H2 receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of receptors, enzymes, and cytoplasmic signal transduction systems, further possibilities exist for the development of effective antisecretory pharmacotherapy. Gastrin CCK2 receptor antagonists and locally active agents appear to represent promising therapies for the future. Development of gene targeting techniques has allowed production of genetically engineered transgenic and knockout mice. Such genetic technology has increased the investigative power for pharmacotherapy for not only antisecretory agents, but also treatment of mucosal diseases, such as atrophy, hyperplasia, and cancer. Elucidation of the origin of gastric parietal cells also represents an interesting investigative target that should allow a better understanding of not only acid-related diseases, but also the evolution of the stomach as an acid-secreting organ.

AB - Pharmacological agents, such as histamine H2 receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of receptors, enzymes, and cytoplasmic signal transduction systems, further possibilities exist for the development of effective antisecretory pharmacotherapy. Gastrin CCK2 receptor antagonists and locally active agents appear to represent promising therapies for the future. Development of gene targeting techniques has allowed production of genetically engineered transgenic and knockout mice. Such genetic technology has increased the investigative power for pharmacotherapy for not only antisecretory agents, but also treatment of mucosal diseases, such as atrophy, hyperplasia, and cancer. Elucidation of the origin of gastric parietal cells also represents an interesting investigative target that should allow a better understanding of not only acid-related diseases, but also the evolution of the stomach as an acid-secreting organ.

KW - Gastric acid secretion

KW - Gastrin/CCK receptor

KW - H receptor

KW - Histidine decarboxylase

KW - M receptor

KW - Ulcer disease

UR - http://www.scopus.com/inward/record.url?scp=0037377569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037377569&partnerID=8YFLogxK

U2 - 10.1016/S0163-7258(03)00015-9

DO - 10.1016/S0163-7258(03)00015-9

M3 - Review article

C2 - 12667890

AN - SCOPUS:0037377569

VL - 98

SP - 109

EP - 127

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -